Key Performance
More- Earnings Score: 34
- Momentum Score: 77
- True Yield: 85
- Financial Health Score: 40
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
AGC Biologics, 수억 달러 규모 요코하마 생산시설 상업 생산 계약 체결
AGC Biologics has secured a multi-year commercial manufacturing contract worth hundreds of millions of dollars with a major global biopharmaceutical company for its new Yokohama facility. The customer will utilize half of the facility's mammalian cell-based production capacity to manufacture five biopharmaceutical products with minimum 35 batches annually. The facility, set to begin operations in 2027, reflects growing demand for geopolitically stable and reliable biopharmaceutical supply chains.
07/28/2026, 6:50 PM • GlobeNewswire
AGC Biologics 斩获横滨基地商业化生产协议，价值数亿美元
AGC Biologics has secured a multi-year commercial manufacturing contract worth hundreds of millions of dollars with an undisclosed international biopharmaceutical company for its new Yokohama facility in Japan. The agreement covers production of five biopharmaceutical products with at least 35 batches annually, reflecting growing industry demand for geopolitically stable and resilient supply chains. The Yokohama site is expected to begin operations in 2027 with 18,000 liters of single-use bioreactor capacity.
07/28/2026, 6:50 PM • GlobeNewswire
The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.
07/24/2026, 9:30 AM • GlobeNewswire
The global Pyridine & Pyridine Derivatives Market is projected to grow from USD 812.04 million in 2025 to USD 1,255.74 million by 2035, at a CAGR of 4.97%. Growth is driven by increasing demand from agrochemical and pharmaceutical industries, with pyridine leading product segments and herbicides dominating applications. Asia Pacific holds the largest market share at 48%, while the U.S. market is expected to reach USD 228.10 million by 2035.
07/23/2026, 6:47 AM • GlobeNewswire
The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.
07/22/2026, 4:49 AM • GlobeNewswire
Mass Spectrometry Market Size Worth USD 14.09 Billion by 2035 | SNS Insider
The global mass spectrometry market is valued at $6.68 billion in 2025 and is projected to reach $14.09 billion by 2035, growing at a CAGR of 7.74%. Growth is driven by pharmaceutical manufacturing, omics research, clinical diagnostics, and precision medicine adoption. North America leads the market while Asia Pacific records the fastest growth at 9.12% CAGR.
07/17/2026, 6:56 AM • GlobeNewswire
The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment growth, while Asia-Pacific emerges as the fastest-growing region. Key players include Roche, Thermo Fisher, Illumina, and Agilent Technologies.
07/17/2026, 6:44 AM • GlobeNewswire
The global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. Strategic consolidation continues with major acquisitions strengthening end-to-end capabilities.
07/15/2026, 6:46 AM • GlobeNewswire
The global biochemistry analyzer market is projected to reach $8.18 billion by 2035, driven by increasing diagnostic testing demand, adoption of fully automated systems, artificial intelligence integration, and rising preventive screening programs. The market encompasses various product types, modalities, and applications across hospitals, diagnostic centers, and research institutions globally.
07/15/2026, 5:24 AM • GlobeNewswire
The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America leads the market while Asia-Pacific is positioned for rapid expansion.
07/13/2026, 7:32 AM • GlobeNewswire
Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGR
The global environmental DNA (eDNA) market is expected to grow at a CAGR of 10.2% from 2026 to 2031, driven by non-invasive species detection methods, stricter environmental regulations, and increasing demand for ecosystem health monitoring. North America leads the market with advanced research infrastructure and strong public-private collaborations, while air sampling and climate change impact assessment segments show particularly strong growth potential.
07/06/2026, 4:49 AM • GlobeNewswire
The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and Europe $19.32 billion by 2035, with Asia-Pacific showing the fastest growth.
07/03/2026, 6:48 AM • GlobeNewswire
The global single-use bioreactors market is projected to experience robust growth with a CAGR of 17.27%, expanding from USD 3.61 billion in 2025 to USD 15.11 billion by 2034. Growth is driven by increasing biopharmaceutical demand, cost efficiency advantages, and technological advancements in bioprocessing. North America is expected to dominate, while Asia-Pacific shows rapid expansion. Major players include Sartorius, Thermo Fisher Scientific, and Cytiva, with recent developments including new product launches and facility expansions.
07/03/2026, 5:12 AM • GlobeNewswire
Sweden's flu diagnostic and treatment market is projected to grow from USD 172.1 million in 2026 to USD 210.3 million by 2031 at a 4.1% CAGR, driven by high influenza burden among elderly populations and increased adoption of molecular diagnostics and targeted antiviral therapies. The market operates within Sweden's centralized healthcare system with key players including Roche, Thermo Fisher Scientific, 3M, and Meridian Bioscience, though growth is constrained by seasonality, regulatory compliance requirements, and supply chain vulnerabilities.
07/03/2026, 4:47 AM • GlobeNewswire
Global Pharmaceutical Filtration Market to Double by 2034: Insights on Driving Factors
The global pharmaceutical filtration market is expected to grow at a CAGR of 8.13% from 2025 to 2034, driven by rising biopharmaceutical demand, CDMO expansion, and increased sterile drug manufacturing. North America leads the market, while Asia-Pacific emerges as a rapidly growing region. Major players are investing in capacity expansion and acquisitions to meet growing demand, though high operational costs and filter clogging challenges persist.
07/03/2026, 4:43 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 07/31/2026
Company Profile
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.